Android Apple

This Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lilly's Weight-Loss Treatments

By Yahoo! Finance   |   3 months ago
This Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lilly's Weight-Loss Treatments

Goldman Sachs predicts the anti-obesity market to reach $100 billion by 2030. Terns Pharmaceuticals may be a strong contender with its promising GLP-1 weight-loss pill. However, investors should be cautious due to the competitive market and uncertainties in the biotech industry.

Read More

Did you find this insightful?

close

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.